Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Treatment of advanced pancreatic cancer with opioid growth factor: phase I.

Smith JP, Conter RL, Bingaman SI, Harvey HA, Mauger DT, Ahmad M, Demers LM, Stanley WB, McLaughlin PJ, Zagon IS.

Anticancer Drugs. 2004 Mar;15(3):203-9.

PMID:
15014352
2.

Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.

Zagon IS, Jaglowski JR, Verderame MF, Smith JP, Leure-Dupree AE, McLaughlin PJ.

Cancer Chemother Pharmacol. 2005 Nov;56(5):510-20. Epub 2005 Jun 10.

PMID:
15947928
3.

Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice.

Zagon IS, Hytrek SD, Smith JP, McLaughlin PJ.

Cancer Lett. 1997 Jan 30;112(2):167-75.

PMID:
9066724
4.

Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture.

Zagon IS, Hytrek SD, McLaughlin PJ.

Am J Physiol. 1996 Sep;271(3 Pt 2):R511-8.

PMID:
8853370
5.

Identification and characterization of opioid growth factor receptor in human pancreatic adenocarcinoma.

Zagon IS, Smith JP, Conter R, McLaughlin PJ.

Int J Mol Med. 2000 Jan;5(1):77-84.

PMID:
10601579
6.
7.

Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.

Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Shirai Y, Nakagawa A, Kawakami H, Uno T, Ito H, Saisho H.

Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):219-24.

PMID:
17189072
8.

Elevated levels of opioid growth factor in the plasma of patients with pancreatic cancer.

Smith JP, Conter RL, Demers TM, McLaughlin PJ, Zagon IS.

Pancreas. 2000 Aug;21(2):158-64.

PMID:
10975710
9.

Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor.

Zagon IS, Smith JP, McLaughlin PJ.

Int J Oncol. 1999 Mar;14(3):577-84.

PMID:
10024694
10.

Opioid growth factor ([Met5]enkephalin) prevents the incidence and retards the growth of human colon cancer.

Zagon IS, Hytrek SD, Lang CM, Smith JP, McGarrity TJ, Wu Y, McLaughlin PJ.

Am J Physiol. 1996 Sep;271(3 Pt 2):R780-6.

PMID:
8853403
11.

Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.

Zagon IS, McLaughlin PJ.

Int J Oncol. 2004 Jun;24(6):1443-8.

PMID:
15138586
12.

Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer.

Kim HM, Bang S, Park JY, Seong J, Song SY, Chung JB, Park SW.

Cancer Chemother Pharmacol. 2009 Feb;63(3):535-41. doi: 10.1007/s00280-008-0836-1. Epub 2008 Oct 1.

PMID:
18828020
13.

Phase I/II trial of hyperfractionated accelerated chemoradiotherapy for unresectable advanced pancreatic cancer.

Tsujie M, Nakamori S, Tanaka E, Nagano H, Umeshita K, Dono K, Sakon M, Inoue T, Inoue T, Monden M.

Jpn J Clin Oncol. 2006 Aug;36(8):504-10. Epub 2006 Jul 19.

PMID:
16855011
14.

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.

Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, Buhl-Jensen P.

Eur J Haematol. 2008 Sep;81(3):170-6. doi: 10.1111/j.1600-0609.2008.01102.x. Epub 2008 May 27.

PMID:
18510700
15.

Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.

Inada S, Tomidokoro T, Fukunari H, Sato T, Hatano T, Nishimura A, Kawauchi Y, Nikkuni K, Shimizu T, Sato T, Yanagi M, Takahashi S, Yoshida H, Sugita M, Hayashi T.

Cancer Chemother Pharmacol. 2009 Jan;63(2):267-73. doi: 10.1007/s00280-008-0736-4. Epub 2008 Apr 1.

PMID:
18379784
16.

Opioid growth factor and the treatment of human pancreatic cancer: a review.

Zagon IS, McLaughlin PJ.

World J Gastroenterol. 2014 Mar 7;20(9):2218-23. doi: 10.3748/wjg.v20.i9.2218. Review.

17.

UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors.

Sastre J, Aranda E, Abad A, Gallego J, Manzano JL, Gómez A, Carrato A, López E, Díaz-Rubio E; TTD Group.

Anticancer Drugs. 2006 Apr;17(4):417-21.

PMID:
16549999
18.

Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study.

Sasada T, Denno R, Tanaka T, Kanai M, Mizukami Y, Kohno S, Takabayashi A.

Am J Clin Oncol. 2008 Feb;31(1):71-8. doi: 10.1097/COC.0b013e31807a328c.

PMID:
18376231
19.

A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer.

Gharibo M, Patrick-Miller L, Zheng L, Guensch L, Juvidian P, Poplin E.

Pancreas. 2008 May;36(4):341-5. doi: 10.1097/MPA.0b013e31815d50f9.

PMID:
18437079
20.

Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.

Zagon IS, Verderame MF, Hankins J, McLaughlin PJ.

Int J Oncol. 2007 Apr;30(4):775-83.

PMID:
17332915

Supplemental Content

Support Center